Thursday, August 20, 2026

CT Contrast & AKI

IV Contrast agents  commonly used for CT. Iodine is an element used in the contrast media. Studies have shown association between contrast and acute kidney injury . The present term used is contrast associated acute kidney injury or post contrast acute kidney injury.

  • Early binding agents used were iodine based with high osmolality agents , osmolalility often exceeding 1500 mosm/kg H20 approaching 5 - 8 times that of normal human serum. By mid 1990S these agents were changed low osmolality or iso osmolar agents.

Contrast Induced Nephropathy

Criteria

  • Serum creatinine increase by 0.3 mg/dl
  • Increase in serum creatinine by 50%
  • Urine output of less than 0.5ml/kg/hr for atleast 6 hours. 

Risk factors
  • eGFR >45 ml/min/1.73m : Normal Risk
  • eGFR 30 -45 ml/min/1.73m2 : Borderline risk 
  • eGFR < 30 : Higher Risk



The Evidence

  • Most literature evidence of CA-AKI is focused on contrast administration in the setting of PCI, where the dose is substantially higher. The dose of iodinated contrast for CT ranges from 60 -100 ml whereas in PCI is 200-600ml. Also the retrospective studies had confounding factors were the disease itself would have caused AKI. 

  • Mehran et al did a study to assess the relationship between dose of iodinated contrast and the risk of AKI or increase in creatinine by 25% or 0.5mg/dl. The  study demonstrated a relationship wherein the odds of AKI were 1.46 for  200 – 400 mL, 1.98 for 400 – 600 mL, and 4.88 for above 600 mL of  contrast.

  • Hinson et al (j.annemergmed. 2016)published a propensity-matched retrospective  study over a 5-year period comparing the development of AKI in patients  who received contrast-enhanced CT (n = 7201), non-contrast enhanced CT (n = 5499), and patients who did not receive a CT (n = 5234).  Defining AKI according to the Kidney Disease Improving Global Out­  comes guidelines, they discovered that 6.7%, 8.9%, and 8.1% of patients  in these groups developed AKI respectively, with no significant differ­ences between groups. All contrast patients received either iohexol or iodixanol  intravenously with a maximum dose of 120 mL. There was no difference  in subsequent development of chronic kidney disease, need for dialysis,  or renal transplantation.

  • Ehmann et al (Intensive Care Med.2023). published a retrospective entropy-balanced  and propensity-balanced observational cohort study of 14,449 hospi­talized patients already meeting criteria for AKI at the time of emer­gency department visit who did or did not receive contrast media. All  patients received 70 - 120 mL of iohexol or iodixanol intravenously.  They found no association between contrast administration and persis­  tent AKI or need for dialysis.

Conclusion
  • The present literature shows that there is no evidence to suggest CA-AKI may be caused by 60 - 120ml of contrast.

Reference
  • Rogers DC, Tadi P. Intravenous Contrast Media in Medical Imaging. [Updated 2023 Mar 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557794/